Home · Peptides · CJC-1295 (with DAC)
THE PEPTIDE APP FIELD GUIDE · Healing SERIES FIELD SPECIMEN
Healing CATEGORY

CJC-1295 (with DAC)

THE GH SUSTAINER

CJC-1295 DAC, GRF (1-29) analog with DAC, CJC-1295 w/ DAC

CJC-1295 with DAC (Drug Affinity Complex) binds to albumin in your blood, extending its half-life to about a week. That means just 1-2 injections weekly produce sustained growth hormone elevation. That's convenient, but the steady GH bleed is less physiologic than the pulsatile pattern your body produces naturally.

CJC-1295 (with DAC)
CJC-1295 (with DAC)
CJC-1295 (with DAC)

CJC-1295 (with DAC) Evidence Snapshot

How these guides are reviewed
REGULATORY STATUS

Not FDA approved · research use only

DOSING GUIDANCE

Reviewed by our clinical team

LINKED EVIDENCE

Sources pending

CONTENT UPDATED

Aug 28, 2026

Dose and schedule recommendations shown below come from The Peptide App Clinical Team. Research links are provided so readers can inspect the supporting evidence directly. Review the sources.

Quick Answers About CJC-1295 (with DAC)

◆

Is CJC-1295 (with DAC) FDA approved?

No. This profile records CJC-1295 (with DAC) as not FDA approved and for research use only.

MORE CONTEXT ›

Review the regulatory and source details on this page for the current context.

◆

What dose does The Peptide App Clinical Team recommend for CJC-1295 (with DAC)?

Dose: 1-2 mg per week (typically split into 2 doses).

MORE CONTEXT ›

Schedule: twice_weekly. Cycle: 8 weeks on, 8 weeks off. This is clinical-team guidance for reference and does not replace individualized instructions from a licensed clinician.

◆

What research supports this CJC-1295 (with DAC) guide?

No linked research sources are currently available on this guide.

MORE CONTEXT ›

Treat the profile as provisional until supporting sources are published.

People wanting fewer injections
Athletes seeking sustained GH elevation
Anti-aging enthusiasts comfortable with extended half-life
Those who can't commit to daily dosing

CJC-1295 (with DAC) Research

Live research temporarily unavailable

The live research feed did not return papers for this page. The curated references below remain available for crawlable source context.